FL-301

N/A

Report date: 2025/05/29 15:40:00

Base Information

Drug NameFL-301
Drug Alias NameCLDN18.2 eADCCNBL-015FL-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovarock Biotherapeutics LtdFlame Biosciences IncShanghai Xinshi Biological Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A